Literature DB >> 21622980

Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF.

Adriaan A Voors1, Beth A Davison, G Michael Felker, Piotr Ponikowski, Elaine Unemori, Gadi Cotter, John R Teerlink, Barry H Greenberg, Gerasimos Filippatos, Sam L Teichman, Marco Metra.   

Abstract

AIMS: We aimed to determine the relation between baseline systolic blood pressure (SBP), change in SBP, and worsening renal function (WRF) in acute heart failure (AHF) patients enrolled in the Pre-RELAX-AHF trial. METHODS AND
RESULTS: The Pre-RELAX-AHF study enrolled 234 patients within 16 h of admission (median 7 h) for AHF and randomized them to relaxin given intravenous (i.v.) for 48 h or placebo. Blood pressure was measured at baseline, at 3, 6, 9, 12, 24, 36, and 48 h and at 3, 4, and 5 days after enrolment. Worsening renal function was defined as a serum creatinine increase of ≥0.3 mg/dL by Day 5. Worsening renal function was found in 68 of the 225 evaluable patients (30%). Patients with WRF were older (73.5 ± 9.4 vs. 69.1 ± 10.6 years; P= 0.003), had a higher baseline SBP (147.3 ± 19.9 vs. 140.8 ± 16.7 mmHg; P= 0.01), and had a greater early drop in SBP (37.9 ± 16.0 vs. 31.4 ± 12.2 mmHg; P= 0.004). In a multivariable model, higher age, higher baseline creatinine, and a greater early drop in SBP, but not baseline SBP, remained independent predictors of WRF. Furthermore, WRF was associated with a higher Day 60 (P= 0.01), and Day 180 (P= 0.003) mortality.
CONCLUSIONS: Worsening renal function in hospitalized AHF patients is related to a poor clinical outcome and is predicted by a greater early drop in SBP. Trial registration clinicaltrials.gov identifier NCT00520806.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21622980     DOI: 10.1093/eurjhf/hfr060

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  28 in total

1.  Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: identifying patients who do not respond to standard therapy.

Authors:  Sean P Collins; Christopher J Lindsell; Alan B Storrow; Gregory J Fermann; Phillip D Levy; Peter S Pang; Neal Weintraub; W Frank Peacock; Douglas B Sawyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

2.  Effect of carperitide on in-hospital mortality of patients admitted for heart failure: propensity score analyses.

Authors:  Masataka Ogiso; Toshiaki Isogai; Yuta Okabe; Kansuke Ito; Masaki Tsuji; Hiroyuki Tanaka
Journal:  Heart Vessels       Date:  2017-02-20       Impact factor: 2.037

3.  Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events.

Authors:  Sean P Collins; Kimberly W Hart; Christopher J Lindsell; Gregory J Fermann; Neal L Weintraub; Karen F Miller; Susan N Roll; Matthew I Sperling; Douglas B Sawyer; Alan B Storrow
Journal:  Eur J Heart Fail       Date:  2012-06-25       Impact factor: 15.534

Review 4.  Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance.

Authors:  A Mebazaa; H Tolppanen; C Mueller; J Lassus; S DiSomma; G Baksyte; M Cecconi; D J Choi; A Cohen Solal; M Christ; J Masip; M Arrigo; S Nouira; D Ojji; F Peacock; M Richards; N Sato; K Sliwa; J Spinar; H Thiele; M B Yilmaz; J Januzzi
Journal:  Intensive Care Med       Date:  2015-09-14       Impact factor: 17.440

Review 5.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

6.  Influence of Titration of Neurohormonal Antagonists and Blood Pressure Reduction on Renal Function and Decongestion in Decompensated Heart Failure.

Authors:  Alexander J Kula; Jennifer S Hanberg; F Perry Wilson; Meredith A Brisco; Lavanya Bellumkonda; Daniel Jacoby; Steven G Coca; Chirag R Parikh; W H Wilson Tang; Jeffrey M Testani
Journal:  Circ Heart Fail       Date:  2015-12-23       Impact factor: 8.790

7.  Reduced Cardiac Index Is Not the Dominant Driver of Renal Dysfunction in Heart Failure.

Authors:  Jennifer S Hanberg; Krishna Sury; F Perry Wilson; Meredith A Brisco; Tariq Ahmad; Jozine M Ter Maaten; J Samuel Broughton; Mahlet Assefa; W H Wilson Tang; Chirag R Parikh; Jeffrey M Testani
Journal:  J Am Coll Cardiol       Date:  2016-05-17       Impact factor: 24.094

8.  Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts.

Authors:  Ashish Parikh; Divyang Patel; Charles F McTiernan; Wenyu Xiang; Jamie Haney; Lei Yang; Bo Lin; Aaron D Kaplan; Glenna C L Bett; Randall L Rasmusson; Sanjeev G Shroff; David Schwartzman; Guy Salama
Journal:  Circ Res       Date:  2013-06-07       Impact factor: 17.367

Review 9.  The acute cardiorenal syndrome: burden and mechanisms of disease.

Authors:  Petra Nijst; Wilfried Mullens
Journal:  Curr Heart Fail Rep       Date:  2014-12

10.  Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Authors:  M Sarwar; C S Samuel; R A Bathgate; D R Stewart; R J Summers
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.